Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi-aventis to acquire Fovea

Sanofi-aventis to acquire Fovea

2nd October 2009

Sanofi-aventis has revealed that it plans to acquire the French biopharmaceutical ophthalmology company Fovea, a privately-held firm that specialises in research and development into the treatment of ocular conditions.

Fovea, which was established in Paris in 2005, has three products in the stages of clinical development, including FOV 1101, an eye drop with a fixed-dose combination of prednisolone and cyclosporine, which is currently in phase II for the treatment of persistent allergic conjunctivitis.

The other products are FOV 2302, an intravitreal formulation of a plasma kallikrein designed to treat retinal vein occlusion induced macular edema, and FOV 2304, a potent antagonist of bradykinin B1 receptors, active by eye drop, which will enter phase I testing by next month for the treatment of diabetic macular oedema.

Christopher Viehbacher, chief executive officer of Sanofi-aventis, said: “Fovea and its unique technology platform represent a major opportunity for Sanofi-aventis in the very promising and dynamically growing ophthalmic area, driven by unmet medical needs and ageing populations.”

Last week, the company made an appearance on the Dow Jones Sustainability Index for 2009 for the third consecutive year.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.